Israeli scientists have begun the first clinical testing of a new drug SIL204, which uses small interfering RNA molecules to reduce the expression of the mutated KRAS gene in patients with locally advanced pancreatic cancer, with the study expected to expand to an additional 166 patients in various countries. (translated)

